AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18492534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 16567913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of magnesium sulphate 250 mg/kg within half an hour of birth and subsequently 125 mg/kg at 24 and 48 hours of life
Number of subjects: 40
Study 16567913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium treatment)
Number of subjects: 40
Study 14563897 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant phenotype (r-PHT) interpretation
Number of subjects: 180
Study 14563897 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual phenotype (v-PHT) interpretation
Number of subjects: 180
Study 14563897 — intervention group
Group type: COMPARATOR
Intervention: VGI interpretation
Number of subjects: 180
Study 10625787 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromer‐coated polyurethane stents (HCPS)
Number of subjects: 83
Study 10625787 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene stents
Number of subjects: 83
Study 9184975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 12
Study 9184975 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 12
Study 9184975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients infected by Pseudomonas aeruginosa
Number of subjects: 12
Study 9184975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciliary ultrastructure in cystic fibrosis patients
Number of subjects: 12
Study 1286497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (mean dose: 0.73 mg)
Number of subjects: 154
Study 1286497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean dose: 8.9 ml)
Number of subjects: 154
Study 3521855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 50
Study 3521855 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine
Number of subjects: 50
Study 31837382 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 41
Study 31837382 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine
Number of subjects: 41
Study 29493118 — intervention group
Group type: EXPERIMENTAL
Intervention: fast-acting insulin aspart (faster aspart)
Number of subjects: 41
Study 26962719 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum dose 1200 mg three times a day)
Number of subjects: 19
Study 26962719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24746549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity dietary intervention delivered via telephone and mail, including low‐literacy self‐help booklets and personalized dietary feedback
Number of subjects: 183
Study 24746549 — intervention group
Group type: COMPARATOR
Intervention: Control group (general population)
Number of subjects: 183
Study 23442389 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 0
Study 23442389 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 0
Study 20841998 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathel
Number of subjects: 77
Study 20841998 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain‐Ibu
Number of subjects: 77
Study 20841998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel
Number of subjects: 77
Study 18165398 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 652
Study 18165398 — intervention group
Group type: COMPARATOR
Intervention: D&C
Number of subjects: 652
Study 15937595 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Caesarean
Number of subjects: 1159
Study 15937595 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 1159
Study 12502656 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 12502656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 0
Study 12502656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10593710 — intervention group
Group type: EXPERIMENTAL
Intervention: Various fixed-dose combination (FDC) formulations of rifampicin
Number of subjects: 0
Study 10593710 — intervention group
Group type: COMPARATOR
Intervention: Reference administered as loose (separate) formulations
Number of subjects: 0
Study 8618186 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Epo (200 units/kg per day for 10 days)
Number of subjects: 40
Study 8618186 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo in TPN solution (200 units/kg per day for 10 days)
Number of subjects: 40
Study 8618186 — intervention group
Group type: COMPARATOR
Intervention: Both groups (subcutaneous and TPN)
Number of subjects: 40
Study 1816481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 70
Study 1816481 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 70
Study 7100224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg intravenously before and every 8 hours for the first 72 hours post-operatively
Number of subjects: 96
Study 7100224 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 96
Study 31634729 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multidisciplinary program
Number of subjects: 184
Study 31634729 — intervention group
Group type: COMPARATOR
Intervention: Standard antiepileptic drugs (AEDs)
Number of subjects: 184
Study 29217600 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-fine beclometasone/formoterol maintenance and reliever therapy (MART)
Number of subjects: 1701
Study 29217600 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 1701
Study 26149665 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure (specifically sexual assault)
Number of subjects: 1815
Study 26149665 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure (specifically violence exposure)
Number of subjects: 1815
Study 26149665 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of childhood traumatic experiences
Number of subjects: 1815
Study 24423311 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion (2 pmol × kg(‐1) × min(‐1))
Number of subjects: 12
Study 24423311 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 22192096 — intervention group
Group type: EXPERIMENTAL
Intervention: Accordion device
Number of subjects: 21
Study 20665055 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (0.2%) alone, 0.7 ml/kg (Group R)
Number of subjects: 44
Study 20665055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.2%) plus tramadol (2 mg/kg), total volume 0.7 ml/kg (Group RT)
Number of subjects: 44
Study 20665055 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (0.2%) alone (Group R)
Number of subjects: 44
Study 20665055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.2%) plus tramadol (2 mg/kg) (Group RT)
Number of subjects: 44
Study 20665055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 17598014 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 20
Study 17598014 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 20
Study 15201783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (0.6 microM in 50 ml of 0.9% NaCl)
Number of subjects: 25
Study 15201783 — intervention group
Group type: COMPARATOR
Intervention: Botulinum-A toxin injections (300 units diluted in 30 ml 0.9% NaCl)
Number of subjects: 25
Study 12066012 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-Kilo Doser (PKD)
Number of subjects: 7
Study 12066012 — intervention group
Group type: COMPARATOR
Intervention: Traditional techniques
Number of subjects: 7
Study 9792371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC (lamivudine) syrup or tablets (4 mg/kg twice daily)
Number of subjects: 162
Study 9792371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 9792371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC (lamivudine)
Number of subjects: 162
Study 8694982 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical flossing device
Number of subjects: 60
Study 8694982 — intervention group
Group type: COMPARATOR
Intervention: Manual flossing
Number of subjects: 60
Study 2655691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 8
Study 2655691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 8
Study 2655691 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 8
Study 2655691 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 8
Study 2655691 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Ibuprofen and Indomethacin)
Number of subjects: 8
Study 28982 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard electrocoagulation
Number of subjects: 300
Study 28982 — intervention group
Group type: COMPARATOR
Intervention: Tubal ring application
Number of subjects: 300
Study 31195902 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 20
Study 31195902 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment only (Control)
Number of subjects: 20
Study 27571420 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 64
Study 27571420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27571420 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group difference favoring idebenone
Number of subjects: 64
Study 27571420 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group difference in IFR
Number of subjects: 64
Study 26048780 — intervention group
Group type: EXPERIMENTAL
Intervention: H4:IC31 (5, 15, 50, or 150 μg with 500nmol IC31)
Number of subjects: 40
Study 26048780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24060297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-IUD
Number of subjects: 200
Study 24060297 — intervention group
Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 200
Study 21789287 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of monitoring via implanted microsensor in the retainer
Number of subjects: 19
Study 21789287 — intervention group
Group type: COMPARATOR
Intervention: Unawareness of monitoring
Number of subjects: 19
Study 21789287 — intervention group
Group type: EXPERIMENTAL
Intervention: Full usage of the retainer
Number of subjects: 19
Study 21789287 — intervention group
Group type: EXPERIMENTAL
Intervention: Misrepresentation of retainer use
Number of subjects: 19
Study 18752926 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat pate fortified with ferrous sulfate
Number of subjects: 17
Study 18752926 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat pate fortified with ferric pyrophosphate encapsulated in liposomes
Number of subjects: 17
Study 18752926 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat pate fortified with ferric pyrophosphate encapsulated in liposomes plus a hemoglobin-based meat pigment
Number of subjects: 17
Study 16449816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine and theophylline (200 mg twice daily)
Number of subjects: 134
Study 16449816 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine and placebo
Number of subjects: 134
Study 15006999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control with GIK
Number of subjects: 141
Study 11775650 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 0
Study 9265948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (5-35 mg/day)
Number of subjects: 580
Study 9265948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (40-280 mg/day)
Number of subjects: 580
Study 9265948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 9265948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 580
Study 9265948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 580
Study 8286256 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemotherapy (PUVA)
Number of subjects: 25
Study 8286256 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band phototherapy (TL-01 UVB)
Number of subjects: 25
Study 2881788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine
Number of subjects: 16
Study 2881788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30636830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaceprol 200 mg thrice daily
Number of subjects: 91
Study 30636830 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 50 mg thrice daily
Number of subjects: 91
Study 26437063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) with target blood concentration of 500 ng/ml
Number of subjects: 107
Study 26437063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) with target blood concentration of 15 ng/ml
Number of subjects: 107
Study 24916909 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization (RAR)
Number of subjects: 418
Study 24916909 — intervention group
Group type: COMPARATOR
Intervention: Standard randomization
Number of subjects: 418
Study 22622699 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK+4C
Number of subjects: 1783
Study 22622699 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK-20C
Number of subjects: 1783
Study 22622699 — intervention group
Group type: COMPARATOR
Intervention: Merck-20C
Number of subjects: 1783
Study 22622699 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK+4C and GSK-20C
Number of subjects: 1783
Study 20736448 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-β (3.33×10^4 U, n=68)
Number of subjects: 138
Study 20736448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=70)
Number of subjects: 138
Study 18828933 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 21
Study 16629922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing health promotion intervention (including health assessment, regular home visits or telephone contacts, health education, coordination of community services, and empowerment strategies)
Number of subjects: 288
Study 16629922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing health promotion intervention
Number of subjects: 288
Study 16629922 — intervention group
Group type: COMPARATOR
Intervention: Usual home care services
Number of subjects: 288
Study 14563464 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocolchicoside (4 mg-2 ml) administered twice daily for 5 days
Number of subjects: 149
Study 11063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise-exposed group (bedframe workers)
Number of subjects: 181
Study 11063406 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure > 90 dBA
Number of subjects: 181
Study 11063406 — intervention group
Group type: COMPARATOR
Intervention: Control groups (light-metal sector and office workers)
Number of subjects: 181
Study 9123925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant as a topical haemostatic agent
Number of subjects: 39
Study 9123925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 39
Study 9123925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 39
Study 9123925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 1480771 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation (AHF) - 42 Gy/30 F/11 days (3 F/day)
Number of subjects: 56
Study 1480771 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 50 Gy/25 F/5 weeks
Number of subjects: 56
Study 1480771 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation (AHF)
Number of subjects: 56
Study 1480771 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 56
Study 1480771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AHF and CF
Number of subjects: 56
Study 6401753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, by mouth)
Number of subjects: 9
Study 6401753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 9
Study 30649365 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (42 mg elemental Fe/d)
Number of subjects: 73
Study 30649365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (5 d/wk for 25 min at 75-85% of age-predicted maximum heart rate)
Number of subjects: 73
Study 30649365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30413211 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh (Parietene Macro™, Medtronic)
Number of subjects: 100
Study 30413211 — intervention group
Group type: COMPARATOR
Intervention: Biological implants (Permacol™, Medtronic)
Number of subjects: 100
Study 30413211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 27054679 — intervention group
Group type: EXPERIMENTAL
Intervention: Three combat rations plus four 250-kcal protein-based bars (PRO, 20 g protein)
Number of subjects: 73
Study 27054679 — intervention group
Group type: EXPERIMENTAL
Intervention: Three combat rations plus four 250-kcal carbohydrate-based bars (CHO, 48 g carbohydrate)
Number of subjects: 73
Study 27054679 — intervention group
Group type: COMPARATOR
Intervention: Three combat rations (CON)
Number of subjects: 73
Study 27054679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohort (all groups)
Number of subjects: 73
Study 24647040 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice on a sequence of key-presses
Number of subjects: 80
Study 24647040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep after practice
Number of subjects: 80
Study 24647040 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization of the trained sequence
Number of subjects: 80
Study 21347864 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants using the same response keys for all tasks
Number of subjects: 0
Study 21347864 — intervention group
Group type: COMPARATOR
Intervention: Participants using separate response keys
Number of subjects: 0
Study 19889062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 0
Study 19889062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 0
Study 19889062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 12 mg
Number of subjects: 0
Study 19889062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18044291 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.4 mg/kg
Number of subjects: 125
Study 18044291 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopental 0.5 mg/kg
Number of subjects: 125
Study 18044291 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 0.5 mg/kg
Number of subjects: 125
Study 18044291 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1 mg/kg
Number of subjects: 125
Study 18044291 — intervention group
Group type: COMPARATOR
Intervention: saline 3 ml
Number of subjects: 125
Study 15817615 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliances (Herbst and twin block)
Number of subjects: 0
Study 15817615 — intervention group
Group type: COMPARATOR
Intervention: Headgear and passive appliances (Andresen activator and its variants)
Number of subjects: 0
Study 12105362 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg/d
Number of subjects: 321
Study 12105362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 12105362 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 321
Study 10394155 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular graft (EVG) treatment (22 patients, 14 bifurcated, 8 tube)
Number of subjects: 162
Study 10394155 — intervention group
Group type: COMPARATOR
Intervention: Traditional resection (140 patients)
Number of subjects: 162
Study 7590615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load (0.75 g/kg BW per os, OGTT)
Number of subjects: 12
Study 7590615 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose bolus (25 g i.v., IVGTT)
Number of subjects: 12
Study 1791269 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 or 2500 lux phototherapy for 2 hours on seven consecutive days
Number of subjects: 17
Study 1791269 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 7204438 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 105
Study 7204438 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 105
Study 30184105 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 mg)
Number of subjects: 0
Study 30184105 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) (100 mg)
Number of subjects: 0
Study 29955768 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcantratinib, 0.5% (wt/wt), applied once daily for 12 weeks
Number of subjects: 15
Study 29955768 — intervention group
Group type: COMPARATOR
Intervention: placebo, applied once daily for 12 weeks
Number of subjects: 15
Study 29955768 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcantratinib, 0.5% (wt/wt), applied once daily for 4 weeks (phase 1b)
Number of subjects: 15
Study 29955768 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcantratinib, 0.5% (wt/wt)
Number of subjects: 15
Study 29955768 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 26418489 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based exercise program (16 weeks)
Number of subjects: 68
Study 24279707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion at 3 months post-transplant
Number of subjects: 0
Study 24279707 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 0